首页> 外文期刊>Protein Expression and Purification >Overexpression of hepatitis B virus surface antigens including the preS1 region in a serum-free Chinese hamster ovary cell line
【24h】

Overexpression of hepatitis B virus surface antigens including the preS1 region in a serum-free Chinese hamster ovary cell line

机译:无血清中国仓鼠卵巢细胞系中包括preS1区在内的乙肝病毒表面抗原的过表达

获取原文
获取原文并翻译 | 示例
       

摘要

Current hepatitis B virus (HBV) vaccines consist of preparations of recombinant HBV major surface antigen (sAg) and are protective in about 90-95% of vaccinated subjects. In improved vaccines, the frequency of nonresponders to the classical vaccine could be reduced by including additional epitopes from the preS-domains of the middle and large surface antigens. In this report, the development and characterization of a CHO cell line for HBsAg, expressing major, middle, and large antigens are described. Despite the previously reported retention of secreted proteins by the preS1 domain, cell lines could be amplified that secreted large amounts of the complete set of antigens. A producer line was established that expressed 1mg HBsAg per 100 ml suspension culture per week during exponential growth. The productivity per cell increased further by at least threefold when the culture reached the stationary phase at high cell densities. In the production cell line, several hundred copies of the HBV vector were integrated at two adjacent sites into chromosome 2. The cell line was adapted to growth in a defined protein-free medium minimizing the risk of adventitious agents introduced by animal derived supplements. The cell line stably produced antigen over several months. In the candidate vaccine, both preS2 and preS1 domains were present at ratios similar to HBsAg from human sera. In summary, a production cell line for an improved HBV vaccine is presented with properties such as high productivity, long term stability of expression, and growth in protein-free media. (C) 2003 Elsevier Science (USA). All rights reserved. [References: 40]
机译:当前的乙型肝炎病毒(HBV)疫苗由重组HBV主要表面抗原(sAg)的制剂组成,对约90-95%的疫苗接种对象具有保护作用。在改良的疫苗中,可以通过包括来自中和大型表面抗原的preS结构域的其他表位来减少对经典疫苗无反应的频率。在此报告中,描述了表达主要,中型和大型抗原的HBsAg CHO细胞系的开发和表征。尽管先前报道了preS1域保留了分泌蛋白,但可以扩增分泌大量抗原的细胞系。建立了一条生产线,该生产线在指数生长期间每100 ml悬浮培养物每周表达1mg HBsAg。当培养物在高细胞密度下达到固定相时,每细胞的生产率进一步提高了至少三倍。在生产细胞系中,将数百份HBV载体在两个相邻位点整合到2号染色体中。使该细胞系适应于在无蛋白质的特定培养基中生长,从而最大程度地减少了动物衍生的补充剂引入不定因子的风险。细胞系在几个月内稳定产生抗原。在候选疫苗中,preS2和preS1域都以与人类血清中HBsAg相似的比例存在。总之,提出了用于改进的HBV疫苗的生产细胞系,其具有诸如高生产率,长期表达稳定性和在无蛋白培养基中生长的特性。 (C)2003 Elsevier Science(美国)。版权所有。 [参考:40]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号